Inventiva S.A. (NASDAQ:IVA) Given Average Recommendation of “Buy” by Analysts

Inventiva S.A. (NASDAQ:IVA) has received a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.00.

A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Inventiva in a report on Monday, April 1st. Canaccord Genuity Group lifted their price objective on Inventiva from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, April 8th.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new stake in shares of Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,490 shares of the company’s stock, valued at approximately $38,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Down 2.2 %

Shares of IVA stock opened at $2.85 on Wednesday. The stock has a fifty day moving average price of $3.32 and a 200 day moving average price of $3.68. Inventiva has a one year low of $2.52 and a one year high of $4.75.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.